LIX1 (Limb and CNS expressed 1) is a conserved cytoplasmic protein with critical roles in developmental patterning and cellular differentiation. During embryonic development, LIX1 is transiently expressed in nascent limb buds and cranial mesenchyme 1, suggesting functions in limb and CNS morphogenesis. LIX1 regulates cell fate decisions through the Hippo signaling pathway, specifically by controlling YAP1/TAZ activity in mesenchymal progenitors 2. Mechanistically, LIX1 interacts with cytoplasmic domains of Fat signaling components and modulates Fat protein stability and localization 3. In cardiac development, LIX1-like proteins coordinate with DCHS1 and septin cytoskeleton to organize extracellular matrix and promote cell-ECM alignment 4. Clinically, LIX1 dysregulation contributes to gastrointestinal stromal tumor (GIST) pathogenesis and therapeutic resistance. LIX1 is upregulated in GISTs and associates with unfavorable prognosis 2. Upon treatment with tyrosine kinase inhibitors, LIX1 becomes further upregulated and mediates MAPK signaling reactivation, promoting imatinib resistance 5. In prostate cancer, reduced LIX1 expression correlates with advanced disease stages and shorter progression-free intervals 6. While feline SMA models suggest LIX1 importance for motor neuron survival 7, LIX1 mutations appear uncommon in human SMA patients 8.